In this review:
PSMA-based radioligand therapies for the treatment of metastatic CRPC
Relugolix treatment confers similar rates of castration resistance as leuprolide
Abiraterone has a higher real-world cardiotoxicity relative to enzalutamide
Updated results from KEYNOTE-365:pembrolizumab plus olaparib for metastatic CRPC
TITAN analyses find that site and burden of metastases impact outcome
68Ga-RM2 a promising PET radiopharmaceutical for biochemically recurrent PC
Yoga may improve quality of life and reduce inflammation in men with PC
Radiotherapy confers a significantly increased risk for secondary malignancy
Sentinel® PCC4 Test shows promise for precise, non-invasive PC diagnosis
Could masitinib be a novel front-line option for metastatic CRPC?
Please login below to download this issue (PDF)